2B 3-prong needle arrays, device, and 4800 vaccine is recurring revenue as ppl need 2 booster shots annually like flu shot. mRNA vaccines from Moderna and Bntx are not boost-able, have short duration. They require at least 4 booster shots per year, which are not feasible since they are not boost-able.
China loves 4800 due to unparalleled no cold store requirement, long duration, working well on mutants due to great B/T cell responses, full length S spike encoding, best safety, using as booster for other vaccines.
4800, device, 3-prong needle array will be run-away Blockbuster annually in Greater China and worldwide including US eventually.
I was pounding the table on the importance of Advaccine, Apollo partnerships while no one here had an inkling of what’s coming.
China regulatory would fast track Ino’s pipeline products unlike FDA and US BP mischievously held them back for Faucci’s babies.
That’s said device/disposable needle array deals in China, SK, India, P3 hold lifted will be immediate term catalysts.
House and Senate overrides DT’s veto of Defense bill.
This could enable DoD to announce $330M funding.
CEPI grant to continue supporting in manufacturing scale-up and COVAX pre-order for LMICs could be announced upon P3 hold lifted.
Analysts now start to realize Ino’s Blockbuster potential and start upgrading Ino.
It’s too risky to short now.
The vaccine is good, but the Cellectra/device will be the honeypot.
The vaccines can be used on Infectious disease/Cancer..... whatever the vaccine used, there will always be the required electroporation device needed for every vaccine given!!
The quiet before the storm was about 8 months of quiet.
This could be one hell of a storm!
